Novo Nordisk A/S
NOV.F
| Exchange: | F |
| Currency | Euro |
| ISIN: | DK0062498333 |
| Primary Ticker: | NOVO-B.CO |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Drug Manufacturers - General |
| Description: | Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. |
| Address: | Novo Alle 1, Bagsvaerd, Denmark, 2880 |
| Website: | https://www.novonordisk.com |
| Full Time Employees: | 69260 |
| Updated On: | 2024-11-09 |
Highlights
| Market Capitalization: | 444924559360 |
| Market Capitalization Mln: | 444924.55 |
| EBITDA: | 133094998016 |
| PE Ratio: | 35.38 |
| PEG Ratio: | 1.63 |
| Book Value: | 27.07 |
| Dividend Share: | 9.9 |
| Dividend Yield: | 0.01 |
| Earnings Share: | 2.84 |
| Most Recent Quarter: | 2024-09-30 |
| Profit Margin: | 0.35 |
| Operating Margin TTM: | 0.47 |
| Return On Assets TTM: | 0.21 |
| Return On Equity TTM: | 0.88 |
| Revenue TTM: | 270583005184 |
| Revenue Per Share TTM: | 60.69 |
| Quarterly Revenue Growth YOY: | 0.21 |
| Diluted Eps TTM: | 2.84 |
| Quarterly Earnings Growth YOY: | 0.22 |
Valuation
| Trailing PE: | 35.38 |
| Forward PE: | 27.32 |
| Price Sales TTM: | 1.64 |
| Price Book MRQ: | 27.67 |
| Enterprise Value: | 442521859401 |
| Enterprise Value Revenue: | 12.19 |
| Enterprise Value Ebitda: | 24.21 |
Shares
| Shares Outstanding: | 3374909952 |
| Shares Float: | 3180144321 |
| Percent Insiders: | 6.06 |
| Percent Institutions: | 37.48 |
Technicals
| Beta: | 0.16 |
| 52 Week High: | 139.45 |
| 52 Week Low: | 86.42 |
| 50 Day MA: | 110.37 |
| 200 Day MA: | 118.58 |
Splits & Dividends
| Forward Annual Dividend Rate: | 1.33 |
| Forward Annual Dividend Yield: | 0.01 |
| Payout Ratio: | 0.46 |
| Ex Dividend Date: | 2024-08-15 |
| Last Split Factor: | 2:1 |
| Last Split Date: | 2023-09-13 |
Earnings
| Report Date: | 2025-04-30 |
| Date: | 2025-03-31 |
| Before After Market: | Before Market |
| Report Date: | 2025-02-05 |
| Date: | 2024-12-31 |
| Before After Market: | Before Market |
| Report Date: | 2024-11-06 |
| Date: | 2024-09-30 |
| Before After Market: | Before Market |
| Date: | 2024-09-30 |